You are here:
Healthcare Brands — OTC & Consumer Health Ownership
Last Updated:February 24, 2026
About This Investor
JP-B-289
Budget guidance is $6.54M – $32.7M. From Japan, they are evaluating both investment and acquisition structures depending on the case. Priority theme: Businesses that handle OTC drugs (i.e., have OTC brands) Businesses that own healthcare product brands. They are prioritizing Priority countries: Thailand, Singapore, Malaysia, Vietnam, Indonesia, Philippines Countries eligible for consideration: Asia. Majority ownership…
Healthcare (OTC / Consumer Health)
Asia, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam
Strategic Synergy
$6.54M - $32.7M
Majority (principle) | Minority (initial) possible
Request Full Investor Profile
Similar Investors
JP-B-124
Priority theme: They are looking for a wide range of
Pharmaceuticals & Chemicals
Asia, Indonesia
Overseas Expansion
$3.27M - $65.4M
Minority / Majority / 100%
JP-B-521
Investment thesis: They are specifically targeting: Nut processors If you
Food Processing
Asia, India, Indonesia
Overseas Expansion
$654K - $6.54M
Minority preferred | Partnerships possible | Majority also ok
JP-B-176
From Japan, they are currently screening targets across Priority Country:
Plastics Manufacturing
ASEAN, Vietnam
Strategic Expansion
$654K - $6.54M
Majority / 100%